Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ganciclovir
Drug ID BADD_D01003
Description An acyclovir analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections.
Indications and Usage For induction and maintenance in the treatment of cytomegalovirus (CMV) retinitis in immunocompromised patients, including patients with acquired immunodeficiency syndrome (AIDS). Also used in the treatment of severe cytomegalovirus (CMV) disease, including CMV pneumonia, CMV gastrointestinal disease, and disseminated CMV infections, in immunocompromised patients.
Marketing Status approved; investigational
ATC Code J05AB06; S01AD09
DrugBank ID DB01004
KEGG ID D00333
MeSH ID D015774
PubChem ID 135398740
TTD Drug ID D05ARP
NDC Product Code 12806-6941; 51754-2500; 12869-803; 59651-108; 24208-535; 42023-173
UNII P9G3CKZ4P5
Synonyms Ganciclovir | Gancyclovir | BW-759 | Ganciclovir Sodium | Ganciclovir, Monosodium Salt | RS-21592 | BIOLF-62 | Cytovene
Chemical Information
Molecular Formula C9H13N5O4
CAS Registry Number 82410-32-0
SMILES C1=NC2=C(N1COC(CO)CO)N=C(NC2=O)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypomagnesaemia14.04.02.001--
Hyponatraemia14.05.04.002--
Hypophosphataemia14.04.03.001--
Hypotension24.06.03.002--
IIIrd nerve paralysis17.04.02.003; 06.05.02.011--Not Available
Infection11.01.08.002--Not Available
Infertility21.03.02.001--Not Available
Injection site abscess12.07.03.021; 11.01.08.023; 08.02.03.021--Not Available
Injection site haemorrhage24.07.01.010; 12.07.03.005; 08.02.03.005--Not Available
Injection site infection08.02.03.019; 11.01.08.005; 12.07.03.008--Not Available
Injection site inflammation12.07.03.009; 08.02.03.008--Not Available
Injection site pain12.07.03.011; 08.02.03.010--Not Available
Injection site phlebitis24.12.03.003; 12.07.03.012; 08.02.03.011--Not Available
Injection site reaction12.07.03.015; 08.02.03.014--
Injection site thrombosis24.01.01.023; 12.07.03.028; 08.02.03.028--Not Available
Insomnia17.15.03.002; 19.02.01.002--
Intestinal ulcer07.04.06.003--Not Available
Intracranial pressure increased17.07.02.002--Not Available
Irritability19.04.02.013; 08.01.03.011--
Jaundice09.01.01.004; 01.06.04.004; 23.03.03.030--Not Available
Jaundice cholestatic09.01.01.005--Not Available
Laboratory test abnormal13.18.01.001--Not Available
Leukopenia01.02.02.001--Not Available
Libido decreased21.03.02.005; 19.08.03.001--
Liver function test abnormal13.03.04.030--Not Available
Lower respiratory tract infection22.07.01.002; 11.01.09.002--Not Available
Lymphadenopathy01.09.01.002--Not Available
Malaise08.01.01.003--
Mania19.16.02.002--
Melaena24.07.02.013; 07.12.02.004--Not Available
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 9 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene